Phase II study of S-1 plus oxaliplatin 130 mg/m2 in Japanese patients with advanced gastric cancer.

Yosuke KitoNozomu MachidaSadayuki KawaiSatoshi HamauchiTakahiro TsushimaAkiko TodakaTomoya YokotaKentaro YamazakiAkira FukutomiYusuke OnozawaKunihiro TsujiHisashi DoyamaYutaka HaraguchiKoji NakashimaKenji KuniedaKeisei TakuKeita MoriHirofumi Yasui

Published in: International journal of clinical oncology (2018)

Results indicated that SOX130 was feasible in Japanese patients with advanced gastric cancer.

Keyphrases

phase ii study
neoadjuvant chemotherapy
locally advanced
open label
rectal cancer
squamous cell carcinoma
transcription factor
stem cells
radiation therapy
lymph node
placebo controlled
clinical trial
randomized controlled trial
study protocol